Bilateral Serous Maculopathy Associated with Acalabrutinib Therapy in Chronic Lymphocytic Leukemia

20260 citationsJournal Article

Authors

Rouzbeh Abbasgholizadeh · University of California, Los Angeles

Alberto Quarta · University of California, Los Angeles

Saghar Bagheri · University of California, Los Angeles

Ceren Soylu · University of California, Los Angeles

Srinivas R. Sadda · University of California, Los Angeles

Abstract

The bilateral, reversible serous maculopathy tightly linked to acalabrutinib exposure supports a drug-related etiology. BTK inhibitors should be considered in cases of new bilateral serous SRF/PEDs, and prompt coordination with oncology may facilitate recovery through systemic therapy modification.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retinal Cases & Brief Reports

DOI: 10.1097/icb.0000000000001911

Field-Weighted Citation Impact: 0.00